VCRE

9.4055.10%
YB

Yasir B. Al-Wakeel

Independent Director

Dr. Yasir B. Al-Wakeel, B.M., B.Ch., MA, serves as Independent Trustee of DRI Capital Inc. since August 2026. He also serves as Chief Executive Officer at Vesalius Therapeutics Inc. since September 2025, as a CEO-Partner at Flagship Pioneering, as an Independent Director at Vicore Pharma Holding AB (publ) since May 7, 2024, as an Independent Non-Executive Director at MaxCyte, Inc. since June 15, 2021, and as a Director at Taha Collective, Inc. Previously, Dr. Al-Wakeel served as an Entrepreneur-in-Residence at SR One Capital Management, LP from 2024 to 2025. He served as Chief Financial Officer and Head of Corporate Development at Kronos Bio, Inc. from August 2020 to September 15, 2023. He served as Chief Financial and Strategy Officer at Neon Therapeutics from July 2017 to May 2020, and as Chief Financial Officer of BioNTech US Inc. from June 2017 to May 2020. At Merrimack Pharmaceuticals, Inc., he served as Chief Financial Officer and Head of Corporate Development from August 11, 2015 to June 9, 2017, and also served as Principal Accounting Officer and Treasurer from March 31, 2017 to June 9, 2017. He was with Credit Suisse from 2008 to 2015, where he served in senior roles including as a Research Analyst from January 2008 to March 2011 and as a Director on the healthcare investment banking team. He also served as a Director at Boston Life Sciences, LLC. He began his career as a practicing physician, holding clinical and academic medical posts in the United Kingdom. Dr. Al-Wakeel is a seasoned biotechnology executive and board member with a track record of building and leading life sciences companies. His combination of clinical, financial, and operational experience positions him to guide biotechnology companies through scaling a business and bringing medicines to patients. Dr. Al-Wakeel holds a B.M. B.Ch. (Doctor of Medicine and Surgery) from the University of Oxford, and an M.A. in Theology and a B.A. from the University of Cambridge.

Positions